Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Trellus Health PLC ( (GB:TRLS) ) just unveiled an update.
Trellus Health plc has issued 19,230,769 new ordinary shares in lieu of cash payment for settlement fees related to its secured convertible loan notes, following shareholder approval at a recent general meeting. The new shares are expected to be admitted to trading on AIM around 2 February 2026, taking the company’s total shares in issue to 180,739,102, which will also represent the total voting rights, and modestly diluting existing shareholders while strengthening the company’s capital position by conserving cash.
The most recent analyst rating on (GB:TRLS) stock is a Hold with a £1.00 price target. To see the full list of analyst forecasts on Trellus Health PLC stock, see the GB:TRLS Stock Forecast page.
Spark’s Take on GB:TRLS Stock
According to Spark, TipRanks’ AI Analyst, GB:TRLS is a Neutral.
The score is held down primarily by weak financial performance—large ongoing losses, negative free cash flow, and declining equity—despite the benefit of having no debt. Technicals are the main positive, with strong momentum above major moving averages, but valuation remains constrained by loss-making results and no indicated dividend yield.
To see Spark’s full report on GB:TRLS stock, click here.
More about Trellus Health PLC
Trellus Health plc is a healthcare company that provides value-based digital solutions to help patients with complex chronic conditions manage their health through Trellus Elevate, a technology-enhanced platform combining data analytics, proprietary resilience-based methodology, and expert coaching. Initially focused on high-cost gastrointestinal diseases such as inflammatory bowel disease, the company targets improved treatment adherence, reduced hospitalisations and emergency visits, and long-term cost savings, while also offering support solutions to pharmaceutical partners from clinical trials through commercialisation.
Average Trading Volume: 1,345,009
Technical Sentiment Signal: Buy
Current Market Cap: £1.62M
See more data about TRLS stock on TipRanks’ Stock Analysis page.